Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

629
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
629
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

669
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
669
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

511
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
511
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

935
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
935

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corticosteroids for treating sepsis in children and adults.

The Cochrane database of systematic reviews·2025
Same author

Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.

The Cochrane database of systematic reviews·2024
Same author

Fludrocortisone with hydrocortisone in sepsis: new evidence in an ongoing debate.

Intensive care medicine·2024
Same author

Sepsis survivors call for the development of a European sepsis plan.

Lancet (London, England)·2024
Same author

Complement system activation: bridging physiology, pathophysiology, and therapy.

Intensive care medicine·2024
Same author

Sepsis from Science to Social Perspective.

Seminars in respiratory and critical care medicine·2024
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.7K

Corticosteroids for treating sepsis.

Djillali Annane1, Eric Bellissant, Pierre Edouard Bollaert

  • 1Critical Care Department, Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris, 104. Boulevard Raymond Poincaré, Garches, Ile de France, France, 92380.

The Cochrane Database of Systematic Reviews
|December 4, 2015
PubMed
Summary
This summary is machine-generated.

Corticosteroids may reduce mortality in sepsis patients. A long course of low-dose corticosteroids appears most effective, though it may increase metabolic disorders. Further research is needed to confirm these findings.

More Related Videos

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

56.6K
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.6K

Related Experiment Videos

Last Updated: Mar 29, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.7K
Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

56.6K
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.6K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Infectious Diseases

Background:

  • Sepsis is a life-threatening condition characterized by infection and organ dysfunction (SOFA score ≥ 2).
  • Impaired corticosteroid metabolism is common in sepsis, suggesting potential therapeutic benefits.
  • Previous reviews on corticosteroids for sepsis were published in 2004, 2010, and 2015.

Purpose of the Study:

  • To evaluate the efficacy of corticosteroids in reducing one-month mortality in sepsis patients.
  • To determine if corticosteroid dosage and treatment duration impact patient outcomes.
  • To assess the influence of corticosteroid therapy on sepsis-related organ failures.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searches conducted across multiple databases (CENTRAL, MEDLINE, EMBASE, LILACS) up to October 2014.
  • Included RCTs comparing corticosteroids to placebo or supportive care in sepsis patients; data extraction and quality assessment performed by multiple reviewers.

Main Results:

  • Corticosteroids significantly reduced 28-day mortality (RR 0.87, 95% CI 0.76 to 1.00), though evidence quality was low due to imprecision and inconsistency.
  • A long course of low-dose corticosteroids demonstrated a significant reduction in 28-day mortality (RR 0.87, 95% CI 0.78 to 0.97) with moderate-quality evidence.
  • Corticosteroids improved shock reversal, reduced SOFA scores, and decreased ICU length of stay without increasing gastroduodenal bleeding, superinfection, or neuromuscular weakness. However, they increased risks of hyperglycemia and hypernatremia.

Conclusions:

  • Low-quality evidence suggests corticosteroids reduce overall mortality in sepsis.
  • Moderate-quality evidence indicates that prolonged, low-dose corticosteroid therapy is associated with reduced 28-day mortality and fewer major complications.
  • Metabolic disturbances, such as hyperglycemia and hypernatremia, are potential adverse effects of corticosteroid treatment in sepsis.